Abstract
In the past 10 years there have been significant advances in the understanding and treatment of metastatic prostate cancer. These include the earlier use of docetaxel chemotherapy, and the use of abiraterone, enzalutamide, radium‐223 and cabazitaxel.1–6 This has led to significant improvements in survival, but has increased the choice and complexity of treatment. In this article, the authors review these advances and look at the sequencing of agents.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call